Description
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.-CASNumber-2227102-46-5-MolecularWeight-158000 (average)-Compound Purity-99.08-SMILES-[Patritumab deruxtecan]-Research_Area-Cancer-Solubility-H2O-Target-Antibody-Drug Conjugates (ADCs)-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related
Did you check our products for animal nutrition?